Nykode Therapeutics Feed

	Tid*
2025-02-26	06:30	Bokslutskommuniké 2024
2024-11-27	07:00	Kvartalsrapport 2024-Q3
2024-08-21	-	Kvartalsrapport 2024-Q2
2024-05-21	-	X-dag ordinarie utdelning NYKD 0.00 NOK
2024-05-16	-	Årsstämma
2024-05-14	-	Kvartalsrapport 2024-Q1
2024-02-28	-	Bokslutskommuniké 2023
2023-11-15	-	Kvartalsrapport 2023-Q3
2023-08-23	-	Kvartalsrapport 2023-Q2
2023-05-16	-	Kvartalsrapport 2023-Q1
2023-05-12	-	X-dag ordinarie utdelning NYKD 0.00 NOK
2023-05-11	-	Årsstämma
2023-02-28	-	Bokslutskommuniké 2022
2022-11-23	-	Kvartalsrapport 2022-Q3
2022-08-24	-	Kvartalsrapport 2022-Q2
2022-05-16	-	Kvartalsrapport 2022-Q1
2022-05-13	-	X-dag ordinarie utdelning NYKD 0.00 NOK
2022-05-12	-	Årsstämma
2022-03-31	-	Bokslutskommuniké 2021
2021-12-22	-	Extra Bolagsstämma 2021
2021-11-17	-	Kvartalsrapport 2021-Q3
2021-08-26	-	Kvartalsrapport 2021-Q2
2021-05-12	-	Kvartalsrapport 2021-Q1
2021-05-06	-	X-dag ordinarie utdelning NYKD 0.00 NOK
2021-05-05	-	Årsstämma
2021-04-21	-	Bokslutskommuniké 2020
2020-11-17	-	Kvartalsrapport 2020-Q3
2020-08-27	-	Kvartalsrapport 2020-Q2
2020-07-07	-	Split NYKD 1:5
2020-07-06	-	Extra Bolagsstämma
2020-05-12	-	Kvartalsrapport 2020-Q1
2020-04-22	-	Extra Bolagsstämma

Land	Norge
Lista	OB Match
Sektor	Hälsovård
Industri	Bioteknik

2024-11-20 18:00:00 Nykode Therapeutics - invitation to Q3 2024 financial results presentation

2024-11-08 15:18:40 Nykode Therapeutics ASA - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider 2,40 NOK | -44,08% | 87,6 MNOK

2024-11-08 15:10:27 NYKD: Disclosure of large shareholding in Nykode Therapeutics ASA 2,40 NOK | -44,08% | 87,6 MNOK

2024-11-08 00:15:00 Nykode Therapeutics - Webcast Invitation 4,29 NOK | +0,42% | 8,22 MNOK

2024-11-07 23:25:00 NYKD: Nykode Therapeutics to Regain Control of VB10.NEO Program 2,40 NOK | -44,08% | 87,6 MNOK

2024-11-06 17:00:00 Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe 4,29 NOK | +0,42% | 8,22 MNOK

2024-11-06 17:00:00 NYKD: Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe 4,29 NOK | +0,42% | 8,22 MNOK

2024-09-27 08:11:20 NYKD: Major shareholding notification 4,60 NOK | -0,86% | 64,2 MNOK

2024-08-21 16:20:12 Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider 5,55 NOK | -47,04% | 164 MNOK

2024-08-21 07:00:00 Nykode Therapeutics - Quarterly report Q2 2024 5,55 NOK | -47,04% | 164 MNOK

2024-08-21 06:30:00 NYKD: Nykode Therapeutics Announces Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer 5,55 NOK | -47,04% | 164 MNOK

2024-08-14 07:00:00 Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines 12,68 NOK | +4,45% | 20,0 MNOK

2024-08-14 07:00:00 NYKD: Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines 12,68 NOK | +4,45% | 20,0 MNOK

2024-08-01 08:00:00 Nykode Therapeutics - invitation to Q2 2024 financial results presentation 14,85 NOK | -1,13% | 12,4 MNOK

2024-07-01 20:20:00 Nykode Therapeutics - Grant of share options 14,61 NOK | -1,81% | 12,8 MNOK

2024-06-20 07:00:00 Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting 15,14 NOK | +4,27% | 29,5 MNOK

2024-06-20 07:00:00 NYKD: Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting 15,14 NOK | +4,27% | 29,5 MNOK

2024-06-11 07:00:04 Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy 16,28 NOK | -0,73% | 53,8 MNOK

2024-06-11 07:00:00 NYKD: Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy 16,28 NOK | -0,73% | 53,8 MNOK

2024-05-24 17:15:00 Nykode Therapeutics - Grant of share options

2024-05-16 11:46:40 Nykode Therapeutics ASA - Minutes of Annual General Meeting 14,67 NOK | -0,41% | 12,5 MNOK

2024-05-14 07:15:00 Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer 14,35 NOK | +2,14% | 25,4 MNOK

2024-05-14 07:15:00 NYKD: Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer 14,35 NOK | +2,14% | 25,4 MNOK

2024-05-14 07:00:00 Nykode Therapeutics - Quarterly report Q1 2024 14,35 NOK | +2,14% | 25,4 MNOK

2024-05-07 07:00:00 Nykode Therapeutics - invitation to Q1 2024 financial results presentation 14,06 NOK | +0,57% | 10,5 MNOK

2024-04-25 07:30:00 Nykode Therapeutics ASA - Notice of Annual General Meeting 12,90 NOK | -3,01% | 15,3 MNOK

2024-04-19 07:00:00 Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer 12,96 NOK | +3,35% | 19,2 MNOK

2024-04-19 07:00:00 NYKD: Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer 12,96 NOK | +3,35% | 19,2 MNOK

2024-04-19 06:30:00 Nykode Therapeutics - Annual Report 2023 12,96 NOK | +3,35% | 19,2 MNOK

2024-03-26 15:30:34 Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider 15,24 NOK | +4,67% | 23,7 MNOK

2024-03-21 19:38:41 Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider 14,91 NOK | +1,43% | 18,3 MNOK

2024-03-21 07:00:00 Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer 14,70 NOK | +1,66% | 52,9 MNOK

2024-03-21 07:00:00 NYKD: Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer 14,70 NOK | +1,66% | 52,9 MNOK

2024-03-19 07:00:00 Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases 14,09 NOK | -0,70% | 28,5 MNOK

2024-03-19 07:00:00 NYKD: Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases 14,09 NOK | -0,70% | 28,5 MNOK

2024-03-13 14:57:58 Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider 14,14 NOK | -5,80% | 56,0 MNOK

2024-03-08 16:16:17 Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider 14,99 NOK | +8,31% | 86,9 MNOK

2024-03-08 13:31:02 Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider 14,99 NOK | +8,31% | 86,9 MNOK

2024-03-04 13:11:51 Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider 15,86 NOK | -6,65% | 69,2 MNOK

2024-02-29 16:27:01 Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider 16,61 NOK | -1,95% | 43,0 MNOK

2024-02-28 07:00:00 Nykode Therapeutics - Quarterly report Q4 2023 16,94 NOK | -5,84% | 75,1 MNOK

2024-02-22 07:00:00 Nykode Therapeutics - invitation to Q4 2023 financial results presentation 17,85 NOK | +1,42% | 13,3 MNOK

2023-12-19 07:00:00 NYKD: Nykode Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference 18,70 NOK | -5,56% | 44,3 MNOK

2023-12-18 21:19:36 NYKD: Financial calendar 18,70 NOK | -5,56% | 44,3 MNOK

2023-12-14 07:00:00 NYKD: Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer 19,39 NOK | +9,55% | 71,2 MNOK

2023-12-07 18:00:46 Nykode Therapeutics - Share capital increase from exercise of warrants 18,00 NOK | +1,12% | 14,5 MNOK

2023-11-28 10:49:37 Nykode Therapeutics - Share capital increase from exercise of warrants 17,92 NOK | -2,13% | 38,3 MNOK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Nykode Therapeutics

Kalender

Beskrivning

Nykode Therapeutics

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden